Founded in 2013, scPharmaceuticals Inc. is commercializing products that advance patient care and reduce healthcare costs by enabling subcutaneous administration at home for products that were previously limited to intravenous (IV) delivery in the hospital setting. FUROSCIX, a pH neutral, subcutaneous formulation of furosemide was FDA approved in October 2022 and launched in February 2023 for the treatment of congestion due to fluid overload in patients with heart failure (HF). A sNDA is pending to expand he indication to chronic kidney disease (CKD) with a PDUFA date of Q1-2025.